Suppr超能文献

对华法林耐药个体中(S)-华法林的高清除率。

High clearance of (S)-warfarin in a warfarin-resistant subject.

作者信息

Hallak H O, Wedlund P J, Modi M W, Patel I H, Lewis G L, Woodruff B, Trowbridge A A

机构信息

College of Pharmacy, University of Kentucky, Lexington 40536-0082.

出版信息

Br J Clin Pharmacol. 1993 Mar;35(3):327-30. doi: 10.1111/j.1365-2125.1993.tb05703.x.

Abstract

A 30 year old black male required a 60 mg daily dose of warfarin to elicit a therapeutic anticoagulant response (normal warfarin dose 2.5-10 mg day-1; maximum 15 mg day-1). Hereditary warfarin resistance was suspected after compliance, diet, concurrent medication and any gastrointestinal disorder were eliminated as contributory causes. The disposition of vitamin K and vitamin K epoxide was examined in the propositus, his two sisters and 13 control black male subjects. Each subject was given an i.v. bolus dose (5 mg) of vitamin K prior to and after 2 weeks of warfarin therapy (5 mg day-1). The oral clearances of (S)- and (R)-warfarin were also measured in each subject during the last day of warfarin therapy. The mean (+/- s.d.) systemic clearance of vitamin K was similar in all subjects before (114 +/- 35 ml min-1) and after (112 +/- 40 ml min-1) warfarin therapy. The mean (+/- s.d.) AUC value for vitamin K epoxide was increased by warfarin treatment (6.5 +/- 5.4 micrograms ml-1 min before and 139 +/- 78 micrograms ml-1 min after) in all subjects. In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively). In one sister of the propositus, the stereoselective disposition of warfarin was comparable with that of her brother ((S)-warfarin clearance = 16.2 ml min-1; and (S)/(R)-warfarin clearance ratio = 2.7).

摘要

一名30岁的黑人男性每天需要60毫克华法林才能产生治疗性抗凝反应(正常华法林剂量为2.5 - 10毫克/天;最大剂量为15毫克/天)。在排除依从性、饮食、同时服用的药物及任何胃肠道疾病等可能的促成因素后,怀疑存在遗传性华法林抵抗。对先证者、他的两个姐妹及13名对照黑人男性受试者进行了维生素K和维生素K环氧化物代谢情况的检查。在华法林治疗(5毫克/天)2周前后,分别给每位受试者静脉注射一剂(5毫克)维生素K。在华法林治疗的最后一天,还测量了每位受试者中(S)-和(R)-华法林的口服清除率。在所有受试者中,华法林治疗前后维生素K的平均(±标准差)全身清除率相似(治疗前为114±35毫升/分钟,治疗后为112±40毫升/分钟)。华法林治疗使所有受试者维生素K环氧化物的平均(±标准差)AUC值升高(治疗前为6.5±5.4微克·毫升-1·分钟,治疗后为139±78微克·毫升-1·分钟)。在先证者中,(S)-华法林的口服清除率(14.5毫升/分钟)及(S)/(R)-华法林的清除率比值(2.6)与对照组(分别为4.3±1.1毫升/分钟和1.2±0.2)相差超过7个标准差。在先证者的一个姐妹中,华法林的立体选择性代谢情况与其兄弟相当((S)-华法林清除率 = 16.2毫升/分钟;(S)/(R)-华法林清除率比值 = 2.7)。

相似文献

1
High clearance of (S)-warfarin in a warfarin-resistant subject.
Br J Clin Pharmacol. 1993 Mar;35(3):327-30. doi: 10.1111/j.1365-2125.1993.tb05703.x.
3
Enantiomers of warfarin and vitamin K1 metabolism.
Br J Clin Pharmacol. 1986 Dec;22(6):729-32. doi: 10.1111/j.1365-2125.1986.tb02966.x.
5
The effect of dietary vitamin K on warfarin-induced anticoagulation.
J Intern Med. 1991 Jun;229(6):517-20. doi: 10.1111/j.1365-2796.1991.tb00388.x.
6
Hereditary warfarin resistance.
South Med J. 1994 Mar;87(3):407-9. doi: 10.1097/00007611-199403000-00023.
7
Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices.
Int J Vitam Nutr Res. 2006 Mar;76(2):65-74. doi: 10.1024/0300-9831.76.2.65.
9
Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.
Clin Pharmacokinet. 1996 Apr;30(4):300-13. doi: 10.2165/00003088-199630040-00003.
10
Conversion of vitamin K epoxide to hydroxyvitamin K by liver microsomes from warfarin-resistant rats.
Nutr Rev. 1983 Aug;41(8):253-4. doi: 10.1111/j.1753-4887.1983.tb07190.x.

引用本文的文献

1
Ethnic Diversity and Warfarin Pharmacogenomics.
Front Pharmacol. 2022 Apr 4;13:866058. doi: 10.3389/fphar.2022.866058. eCollection 2022.
4
Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
Ir J Med Sci. 2014 Jun;183(2):161-72. doi: 10.1007/s11845-013-0978-y. Epub 2013 Jun 27.
5
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.
Br J Clin Pharmacol. 2012 Jul;74(1):86-97. doi: 10.1111/j.1365-2125.2012.04181.x.
6
In silico pharmacogenetics of warfarin metabolism.
Nat Biotechnol. 2006 May;24(5):531-6. doi: 10.1038/nbt1195.
7
Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.
J Thromb Thrombolysis. 2002 Dec;14(3):227-32. doi: 10.1023/a:1025052827305.
8
Pharmacogenetics: the therapeutic drug monitoring of the future?
Clin Pharmacokinet. 2001;40(11):783-802. doi: 10.2165/00003088-200140110-00001.
9
Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.
Clin Pharmacokinet. 1996 Apr;30(4):300-13. doi: 10.2165/00003088-199630040-00003.

本文引用的文献

1
The physiological disposition of dicumarol in man.
J Pharmacol Exp Ther. 1950 Aug;99(4:1):409-20.
3
Warfarin resistance and vitamin K.
Ann Intern Med. 1981 Jan;94(1):140-1. doi: 10.7326/0003-4819-94-1-140_3.
4
Interaction of secobarbital with warfarin pseudoracemates.
Clin Pharmacol Ther. 1980 Aug;28(2):187-95. doi: 10.1038/clpt.1980.149.
5
"Resistance" to warfarin due to unrecognized vitamin K supplementation.
N Engl J Med. 1980 Jul 17;303(3):160-1. doi: 10.1056/nejm198007173030317.
6
Liquid nutrition as a cause of warfarin resistance.
Am J Hosp Pharm. 1981 Aug;38(8):1174.
8
Familial warfarin resistance.
Drug Intell Clin Pharm. 1983 Apr;17(4):281-3. doi: 10.1177/106002808301700409.
9
Effect of enteral nutrition on warfarin therapy.
Clin Pharm. 1982 May-Jun;1(3):274-6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验